AMIX 10-K

Autonomix Medical, Inc. (AMIX)

10-K 2026-05-27 For: 2026-03-31

View Original

Added on May 28, 2026

Delaware				47-1607810
(State or Other Jurisdiction of				(I.R.S. Employer Identification No.)
Incorporation or Organization)

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value	AMIX	The Nasdaq Stock Market

Large accelerated filer	☐		Accelerated filer	☐		Non-accelerated filer	☒		Smaller reporting company	☒
									Emerging growth company	☒

PART I

Item 1.	Business	5
Item 1A.	Risk Factors	14
Item 1B.	Unresolved Staff Comments	34
Item 1C.	Cybersecurity	34
Item 2.	Properties	35
Item 3.	Legal Proceedings	35
Item 4.	Mine Safety Disclosures	35

PART II

Item 5.	Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	36
Item 6.	Reserved	36
Item 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	36
Item 7A.	Quantitative and Qualitative Disclosure About Market Risk	41
Item 8.	Financial Statements and Supplementary Data	41
Item 9.	Changes in and Disagreements with Accountants on Accounting and Financial Disclosures	64
Item 9A.	Controls and Procedures	64
Item 9B.	Other Information	65
Item 9C.	Disclosure Regarding Foreign Jurisdictions that Prevent Inspections	65

PART III		66

Item 10.	Directors, Executive Officers and Corporate Governance	66
Item 11.	Executive Compensation	66
Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	66
Item 13.	Certain Relationships and Related Transactions and Director Independence	66
Item 14.	Principal Accounting Fees and Services	66

PART IV		67

Item 15.	Exhibits, Financial Statement Schedules	67
Item 16.	Form 10-K Summary	69

	•	our ability to continue as a going concern in the near term is dependent upon us successfully raising additional equity or debt financing to fund our operations;
	•	the success of our future clinical trials;
	•	we currently have no source of product sales revenue;
	•	competition from existing products or new products that may emerge;
	•	if we fail to comply with U.S. and foreign regulatory requirements, regulatory authorities could limit or withdraw any marketing or commercialization approvals we may receive and subject us to other penalties that could materially harm our business;
	•	we may be unable to obtain U.S. or foreign regulatory approval and, as a result, unable to commercialize our product candidates;
	•	the implementation of our business model and strategic plans for our business, technologies and product candidates;
	•	potential product liability claims;
	•	our dependency on third-party supply and manufacturing partners to supply the materials and components for, and manufacture, our research and development, preclinical and clinical trial devices;
	•	our ability to establish or maintain collaborations, licensing or other arrangements and retain commercial rights for our product candidates subject to collaborations;
	•	our ability and third parties’ abilities to protect intellectual property rights and our ability to operate our business without infringing the intellectual property rights of others;
	•	our ability to adequately support future growth;
	•	our estimates of our expenses, ongoing losses, future revenue and capital requirements;
	•	our ability to attract and retain key management personnel and technical personnel to manage our business effectively;
	•	risks associated with our identification of material weaknesses in our control over financial reporting;
	•	our use of net proceeds received by us from any subsequent private placement or public financing;

	•	natural disasters affecting us, our primary manufacturer or our suppliers;
	•	our ability to establish relationships with health care professionals and organizations;
	•	general economic uncertainty that adversely affects spending on medical procedures;
	•	our ability to maintain the listing of our common stock on the Nasdaq Capital Market;
	•	volatility in the market price of our stock; and
	•	potential dilution to current stockholders from the issuance of equity awards.

	•	Class I devices, which are subject to only general controls (e.g., labeling, medical devices reporting, and prohibitions against adulteration and misbranding) and, in some cases, to the premarket clearance requirements;
	•	Class II devices, generally requiring premarket clearance before they may be commercially marketed in the United States; and
	•	Class III devices, consisting of devices deemed by the FDA to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices, or devices deemed not substantially equivalent to a predicate device, generally requiring submission of a PMA supported by clinical trial data.

	•	Product listing and establishment registration, which helps facilitate FDA inspections and other regulatory action;
	•	Quality System Regulation, or QSR, which requires manufacturers, including third-party manufacturers, to follow stringent design, testing, control, documentation and other quality assurance procedures during all aspects of the manufacturing process;
	•	labeling regulations and FDA prohibitions against the promotion of products for uncleared, unapproved or off-label use or indication;
	•	clearance of product modifications that could significantly affect safety or efficacy or that would constitute a major change in intended use of one of our cleared devices;
	•	approval of product modifications that affect the safety or effectiveness of one of our approved devices;
	•	medical device reporting regulations, which require that manufacturers comply with FDA requirements to report if their device may have caused or contributed to a death or serious injury, or has malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction of the device or a similar device were to recur;
	•	post-approval restrictions or conditions, including post-approval study commitments;
	•	post-market surveillance regulations, which apply when necessary to protect the public health or to provide additional safety and effectiveness data for the device;
	•	the FDA's recall authority, whereby it can ask, or under certain conditions order, device manufacturers to recall from the market a product that is in violation of governing laws and regulations;
	•	regulations pertaining to voluntary recalls; and
	•	notices of corrections or removals.

	•	untitled letters, warning letters, fines, injunctions, consent decrees and civil penalties;
	•	unanticipated expenditures to address or defend such actions
	•	customer notifications for repair, replacement, refunds;
	•	recall, detention or seizure of our products;
	•	operating restrictions or partial suspension or total shutdown of production;
	•	refusing or delaying our requests for premarket clearance or premarket approval of new products or modified products;
	•	operating restrictions;
	•	withdrawing premarket clearances or PMA approvals that have already been granted;
	•	refusal to grant export approval for our products; or
	•	criminal prosecution.

	•	Factors raise substantial doubt about our ability to continue as a going concern;
	•	We have no approved products, and we cannot assure you that we will generate revenue or become profitable in the future;
	•	We will need additional financing over the longer term to execute our business plan and fund operations, which additional financing may not be available on reasonable terms or at all;
	•	We intend to utilize a single manufacturer for the manufacture of our lead product candidate and expect to continue to do so for commercial products. Risks associated with the manufacturing of our products could reduce our gross margins and negatively affect our operating results;
	•	We are a developmental stage Company and have not yet had a history of generating revenue;
	•	Our business may be adversely affected by the state of the global economy, uncertainties in global financial markets, and possible trade tariffs and trade restrictions;

	•	We have limited experience in assembling and testing our products and may encounter problems or delays in the assembly of our products or fail to meet certain regulatory requirements which could result in an adverse effect on our business and financial results;
	•	Rapidly changing technology in life sciences could make the products we are developing obsolete;
	•	Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults, or non-performance by financial institutions or transactional counterparties, could adversely affect our current and projected business operations and our financial condition and results of operations;
	•	We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights;
	•	Catastrophic events and disaster recovery may disrupt business continuity;
	•	We may fail to meet the Sarbanes-Oxley regulations and may lack the financial controls and safeguards required of public companies;
	•	While our Company’s management is working to improve our internal controls and procedures, at present management has determined that our internal controls were deemed to be inadequate, which could cause our financial reporting to be unreliable and lead to misinformation being disseminated to the public;
	•	Because of the specialized nature of our business, the termination of relationships with our key employees, consultants and advisors may prevent us from successfully operating our business, including developing our products, conducting clinical studies, commercializing our products and obtaining any necessary financing; and

	•	Changes to United States federal and state regulatory agencies may cause disruptions and delays in approval of the government approval processes and regulation relating to our products;
	•	There is no guarantee that the FDA will grant 510(k) or de novo clearance or a premarket approval application (“PMA”) of our future products and failure to obtain necessary clearances or approvals for our future products would adversely affect our ability to grow our business;
	•	Our product development for our sensing and ablation technologies may not meet the necessary validation requirements to achieve regulatory approvals, or our internal specifications for commercial viability;
	•	Modifications to our future products may require new regulatory clearances or approvals or may require us to recall or cease marketing our products until clearances or approvals are obtained;
	•	The results of our future clinical trials may not support our product candidate claims or may result in the discovery of adverse side effects;
	•	We are conducting our initial Proof of Concept trial outside the United States using commercially available RF ablation equipment in a new anatomical region to assess clinical response. We plan to present the relevant data from this trial to the FDA to support the clinical requirements for clearance in the United States. However, there is no assurance that the FDA will accept this data;
	•	Our clinical studies could be delayed or otherwise adversely affected by many factors, including difficulties in enrolling patients;
	•	We may have limitations in generating statistically significant long-term clinical data and gaining extended-duration indications from clinical studies involving terminal patients;
	•	Even if our products are cleared or approved by the FDA, if we or our suppliers fail to comply with ongoing FDA requirements, or if we experience unanticipated problems with our products, these products could be subject to restrictions or withdrawal from the market;
	•	Our products may in the future be subject to product recalls that could harm our reputation, business, and financial results;
	•	If our products cause or contribute to a death or a serious injury, or malfunction in certain ways, we will be subject to medical device reporting regulations, which can result in voluntary corrective actions or agency enforcement actions;
	•	Certain parts used in the manufacturing of our equipment may experience shortages in global supply which could impact our ability to manufacture our device for customers or maintain research and development timelines;
	•	U.S. legislative or FDA regulatory reforms may make it more difficult and costly for us to obtain regulatory approval of our product candidates and to manufacture, market and distribute our products after approval is obtained;
	•	Failure to secure and maintain adequate coverage and reimbursement from third-party payers could adversely affect acceptance of our products, if approved, and reduce our revenues;
	•	We may not be successful in securing and maintaining reimbursement codes necessary to facilitate accurate and timely billing for our products or physician services attendant to our products;
	•	If we are unable to establish good relationships with physicians, our business could be negatively affected; and
	•	There is no assurance that Medicare or the Medicare Administrative Contractors will provide coverage or adequate payment rates for our products.

	•	If third parties claim that our products infringe their intellectual property rights, we may be forced to expend significant financial resources and management time defending against such actions and our financial condition and our results of operations could suffer;
	•	If we are unable to protect the intellectual property used in our products, others may be able to copy our innovations which may impair our ability to compete effectively in our markets;
	•	We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers;
	•	If we are unable to protect the confidentiality of our proprietary information and know-how, the value of our technology and products could be adversely affected; and
	•	We may not be able to protect our intellectual property rights throughout the world.

	•	Our business and operations would suffer in the event of third-party computer system failures, cyberattacks on third-party systems or deficiency in our cybersecurity;
	•	Artificial intelligence presents risks and challenges that can impact our business, including by posing security risks to our confidential information, proprietary information and personal data; and
	•	Cybersecurity risks and cyber incidents could adversely affect our business and disrupt operations.

	•	We are not in compliance with Nasdaq’s continued listing requirements and if we are unable to regain compliance with the listing requirements, our common stock will be delisted from Nasdaq which could have a material adverse effect on our financial condition and could make it more difficult for stockholders to sell their shares;
	•	We do not intend to pay cash dividends on our common stock in the foreseeable future;
	•	If our stock price fluctuates, you could lose a significant part of your investment;
	•	Techniques employed by short sellers may in the future drive down the market price of our common stock;
	•	If securities or industry analysts do not publish research or reports about us, or if they adversely change their recommendations regarding our common stock, then our stock price and trading volume could decline;
	•	The market price of our stock may be highly volatile, and you could lose all or part of your investment;
	•	Your ownership may be diluted if additional capital stock is issued to raise capital, to finance acquisitions or in connection with strategic transactions;
	•	We may be required to issue up to 271,846 shares of common stock in connection with the reverse stock split we completed on October 24, 2024, and we may be subject to potential liability if it is determined that we are required to issue such shares and fail to issue such shares on a timely basis;
	•	The sale of our common stock by our stockholders, or the perception that stock sales may occur, could cause the price of our common stock to decline.
	•	Provisions of the Series A, B and C Warrants we issued could discourage an acquisition of us by a third party.

	•	inability to secure product components in a timely manner, insufficient quantities or on commercially reasonable terms;
	•	failure to increase production to meet demand;
	•	inability to modify production lines to enable us to efficiently produce future products or implement changes in current products in response to regulatory requirements;

	•	Preventive Controls: We rely on our third-party SaaS providers to deploy advanced firewalls, endpoint protection and intrusion detection systems to secure the infrastructure supporting our operations. Multi-factor authentication and encryption are enforced across critical systems and data repositories.
	•	Monitoring and Detection: Continuous monitoring of our IT environment is facilitated through our third-party service provider.
	•	Incident Response: We maintain an incident response plan that outlines procedures for containment, eradication, and recovery from cybersecurity incidents.
	•	Employee Training: All employees receive mandatory cybersecurity awareness training at onboarding, covering phishing prevention, secure data handling and how to recognize common attack strategies and reporting suspicious activities.

	•	Due diligence reviews of third-party vendors’ cybersecurity policies and practices prior to, and during, potential engagement; and
	•	Contractual requirements for third-party vendors to maintain robust security controls, where applicable, and report incidents promptly.

	Year Ended March 31,
					Change		Change
	2026		2025		( $ )		( % )
Operating expenses:
Research and development	$	7,144	$	4,725	$	2,419		51	%
General and administrative		9,890		6,863		3,027		44	%
Total operating expenses	$	17,034	$	11,588	$	5,446		47	%

	•	difficulty identifying and qualifying alternative manufacturers in a timely manner;
	•	inability to establish agreements with future third-party manufacturers or to do so on acceptable terms; or
	•	potential damage to or destruction of our manufacturers' equipment or facilities.

	•	managing production yields;
	•	maintaining quality control and assurance;
	•	providing component and service availability;
	•	maintaining adequate control policies and procedures;
	•	hiring and retaining qualified personnel; and
	•	complying with state, federal and foreign regulations.

	•	delayed access to deposits or other financial assets or the uninsured loss of deposits or other financial assets;
	•	inability to enter into credit facilities or other working capital resources;
	•	potential or actual breach of contractual obligations that require us to maintain letters of credit or other credit support arrangements; or
	•	termination of cash management arrangements and/or delays in accessing or actual loss of funds subject to cash management arrangements.

	•	pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;
	•	provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and/or directors of the Company; and
	•	provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the financial statements.

	•	the severity of the disease under investigation;
	•	the limited size and nature of the patient population;
	•	the patient eligibility criteria defined in our protocol and other clinical study protocols;
	•	the nature of the study protocol, including the attractiveness of, or the discomforts and risks associated with, the treatments received by enrolled subjects;
	•	difficulties and delays in clinical studies that may occur as a result of public health emergencies or pandemics;
	•	the ability to obtain institutional review board (“IRB”) approval at clinical study locations;
	•	clinicians’ and patients’ perceptions as to the potential advantages, disadvantages and side effects of our products in relation to other available therapies, including any new drugs or treatments that may be approved for the indications we are pursuing;
	•	the possibility or perception that enrolling in a product’s clinical study may limit the patient’s ability to enroll in future clinical studies for other therapies due to protocol restrictions;
	•	the possibility or perception that our software is not secure enough to maintain patient privacy;
	•	the ability to monitor patients adequately during and after treatment;

	•	the availability of appropriate clinical study investigators, support staff, drugs and other therapeutic supplies and proximity of patients to clinical sites;
	•	physicians’ or our ability to obtain and maintain patient consents; and
	•	the risk that patients enrolled in clinical studies will choose to withdraw from or otherwise not be able to complete a clinical study.

	Page
Report of Independent Registered Public Accounting Firm	43
Balance Sheets as of March 31, 2026 and 2025	44
Statements of Operations for the years ended March 31, 2026 and 2025	45
Statements of Changes in Stockholders' Equity for the years ended March 31, 2026 and 2025	46
Statements of Cash Flows for the years ended March 31, 2026 and 2025	47
Notes to Financial Statements	48

(in thousands, except par value and share data)	As of
	March 31,
	2026			2025

Assets
Current assets:
Cash and cash equivalents	$	7,004		$	9,136
Other current assets		577			473
Total current assets		7,581			9,609
Noncurrent assets:
Property and equipment, net		19			21
Deferred offering costs		—			176
Total noncurrent assets		19			197

Total Assets	$	7,600		$	9,806

Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$	700		$	676
Accrued expenses		1,005			1,031
Total current liabilities		1,705			1,707

Total Liabilities		1,705			1,707

Commitments and contingencies (Note 4)

Stockholders' equity:
Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of March 31, 2026 and 2025, respectively		—			—
Common stock, $0.001 par value, 500,000,000 shares authorized, 11,409,344 and 2,497,033 shares issued and outstanding as of March 31, 2026 and 2025, respectively		11			2
Additional paid-in capital		72,978			58,476
Accumulated deficit		(67,094	)		(50,379	)
Total Stockholders' Equity		5,895			8,099

Total Liabilities and Stockholders' Equity	$	7,600		$	9,806

	For the Years Ended
	March 31,
(in thousands, except share and per share data)	2026			2025

Operating expenses:
Research and development	$	7,144		$	4,725
General and administrative		9,890			6,863

Total operating expenses		17,034			11,588

Loss from operations		(17,034	)		(11,588	)

Other income (expense):
Interest expense		—			(176	)
Interest income		319			354

Total other income, net		319			178

Loss before income taxes		(16,715	)		(11,410	)

Income taxes		—			—

Net loss	$	(16,715	)	$	(11,410	)

Loss per share - basic and diluted	$	(2.32	)	$	(6.46	)

Weighted average shares outstanding - basic and diluted		7,216,757			1,766,425

					*Additional*					*Total*
	*Common Stock*				*Paid-in*		*Accumulated*			*Stockholders'*
(in thousands)	*Shares*		*Amount*		*Capital*		*Deficit*			*Equity*

Balance March 31, 2024		943	$	1	$	46,596	$	(38,969	)	$	7,628

Net loss		—		—		—		(11,410	)		(11,410	)
Stock-based compensation		—		—		1,628		—			1,628
Issuance of common stock		13		—		103		—			103
Issuance of common stock - warrants exercised		892		1		—		—			1
Issuance of common shares and equity classified warrants, net of offering costs		616		—		8,972		—			8,972
Issuance of common stock for extinguishment of convertible debt		33		—		1,177		—			1,177

Balance March 31, 2025		2,497		2		58,476		(50,379	)		8,099

Net loss		—		—		—		(16,715	)		(16,715	)
Stock-based compensation		—		—		529		—			529
Stock option cancellations, unamortized stock-based compensation		—		—		3,732		—			3,732
Issuance of common stock for equity line of credit commitment fee		262		—		267		—			267
Issuance of common stock, net of costs		2,395		3		3,211		—			3,214
Issuance and exercise of pre-funded warrants, net of costs		4,502		4		—		—			4
Issuance of common stock - warrants exercised, net of costs		1,753		2		6,763		—			6,765

Balance March 31, 2026		11,409	$	11	$	72,978	$	(67,094	)	$	5,895

	For the Years Ended March 31,
(in thousands)	2026			2025

Cash Flows from Operating Activities:
Net loss	$	(16,715	)	$	(11,410	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation		529			1,628
Stock option cancellations		3,732			—
Issuance of common stock for equity line of credit commitment fee		267			—
Depreciation and amortization expense		12			183
Issuance of common stock, net of discount for lack of marketability		—			101
Changes in operating assets - (increase)/decrease:
Other current assets		(104	)		310
Changes in operating liabilities - increase/(decrease):
Accounts payable		24			184
Accrued expenses		(27	)		746
Net cash used in operating activities		(12,282	)		(8,258	)

Cash Flows from Investing Activities:
Purchase of property and equipment		(10	)		(14	)
Net cash used in investing activities		(10	)		(14	)

Cash Flows from Financing Activities (increase/decrease):
Gross proceeds from issuance of common stock		3,531			—
Direct financing costs for issuance of common stock		(141	)		—
Gross proceeds from warrant inducement		2,546			—
Direct transaction costs for warrant inducement		(291	)		—
Gross proceeds from issuance and exercises of pre-funded warrants		5,000			—
Direct financing costs for issuance of pre-funded warrants		(485	)		—
Gross proceeds from issuance of common stock, pre-funded and common warrants		—			10,025
Direct transaction costs for issuance of common stock, pre-funded and common warrants		—			(1,052	)
Payment of issuance costs for registration statement		—			(176	)
Gross proceeds from exercise of warrants		—			1
Proceeds from sales of common stock		—			2
Net cash provided by financing activities		10,160			8,800

Net change in cash and cash equivalents		(2,132	)		528

Cash and cash equivalents, at beginning of period		9,136			8,608

Cash and cash equivalents, at end of period	$	7,004		$	9,136

Supplemental cash flow disclosures:
Non-cash financing activities:
Recognition of deferred financing costs associated with issuance of common stock	$	(176	)	$	—
Proceeds from cashless exercise of warrants	$	1		$	39
Warrants issued for equity issuance costs	$	—		$	479
Convertible notes converted into common stock	$	—		$	1,330
Settlement/conversion to common shares for debt issuance costs	$	—		$	(153	)

	March 31,
	2026		2025

Accrued compensation	$	593	$	626
Accrued clinical research costs		275		134
Accrued product development costs		30		111
Accrued professional fees		38		52
Accrued franchise tax		50		50
Accrued director fees		—		46
Other miscellaneous accrued expenses		19		12

Total accrued expenses	$	1,005	$	1,031

	*March 31,*
	*2026*		*2025*

Equity based warrants to purchase common shares		4,334		87,531
Bridge financing warrants		25,003		25,003
Stock options granted		13,500		243,483
Series A warrants		55,500		1,533,096
Series B warrants		1,477,596		—
Series C warrants		9,003,332		—
Representative Warrants		180,641		91,985

Total potentially dilutive securities		10,759,906		1,981,098

	*Warrants*		*Weighted-Average Exercise Price Per Share*		*Remaining Life (In Years)*		Aggregate Intrinsic Value*

Outstanding and exercisable, March 31, 2024		25,003	$	20.00		4.48	$	1,010,000

Outstanding and exercisable, March 31, 2025		25,003	$	20.00		3.48	$	—

Outstanding and exercisable, March 31, 2026		25,003	$	20.00		2.48	$	—

	*Year ended March 31,*
	*2026*		*2025*
Recognized in general and administrative expense	$	—	$	116,375

Total	$	—	$	116,375

	*Options*			*Weighted-Average Exercise Price Per Share*		*Weighted-Average Remaining Life (In Years)*		Aggregate Intrinsic Value*

Outstanding, March 31, 2024		100,180		$	46.59		9.35	$	1,680,672
Granted		143,303			23.02		—		—
Outstanding, March 31, 2025		243,483		$	32.72		8.92		—

Exercisable, March 31, 2025		37,923		$	44.35		8.20		—


Outstanding, March 31, 2025		243,483		$	32.72		8.92		—
Granted		5,000			1.85		—		—
Forfeited/Cancelled		(234,983	)		33.67		—		—

Outstanding, March 31, 2026		13,500		$	4.75		8.37		—

Exercisable, March 31, 2026		2,875		$	15.21		5.99		—

						%
	*Year Ended March 31, 2026*
	*Amount*			*Percent*
Federal benefit at statutory rate	$	(3,510	)		21.00	%
Nontaxable or nondeductible items:
Cancellation of prior stock compensation deferred tax asset		1,360			(8.13	)%
Equity-based compensation		8			(0.06	)%
State tax expense		(53	)		0.32	%
Valuation allowance		2,195			(13.13	)%
Effective income tax rate	$	—			—	%

	*Year Ended March 31, 2025*
	*Amount*			*Percent*
Tax benefit at the U.S. federal statutory rate	$	(2,396	)		21.00	%
Permanent differences		5			(0.05	)%
Return to provision		(44	)		0.39	%
Change in state rate		234			(2.05	)%
State tax (net of federal benefit)		(63	)		0.55	%
Valuation allowance		2,264			(19.84	)%
Effective income tax rate	$	—			—	%

Exhibit Number	Description of Document

3.1	Amended and Restated Certificate of Incorporation of Autonomix Medical, Inc. (incorporated by reference from exhibit 2.1 of the Form 1-A POS, file number 024-12296, filed January 19, 2024)

3.2	Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Autonomix Medical, Inc., filed with the Secretary of State of the State of Delaware (incorporated by reference from exhibit 3.1 of the Form 8-K filed October 28, 2024)

3.3	Amended and Restated Bylaws of Autonomix Medical, Inc. dated August 12, 2025 (incorporated by reference from exhibit 3.4 of the Form 10-Q filed August 13, 2025)

4.1	Form of Warrant Agreement issued in SAFE offering (incorporated by reference from exhibit 3.1 of the Form 1-A POS, file number 024-12296, filed January 19, 2024)

4.2	Form of Selling Agent Warrant (incorporated by reference from exhibit 3.2 of the Form 1-A POS, file number 024-12296, filed January 19, 2024)

4.3	Form of Pre-Funded Warrant issued in November 2024 offering (incorporated by reference from exhibit 4.1 of the Form 8-K filed November 25, 2024)

4.4	Form of Series A Warrant issued in November 2024 offering (incorporated by reference from exhibit 4.2 of the Form 8-K filed November 25, 2024)

4.5	Form of Representative’s Warrant issued in November 2024 offering (incorporated by reference from exhibit 4.4 of the Form 8-K filed November 25, 2024)

4.6	Warrant Agency Agreement, dated November 22, 2024, with Equity Stock Transfer, LLC (incorporated by reference from exhibit 4.3 of the Form 8-K filed November 25, 2024)

4.7*	Description of the Company's Securities

4.8	Form of Series B Warrant issued in July 2025 offering (incorporated by reference from exhibit 4.1 of the Form 8-K filed July 22, 2025)

4.9	Form of Pre-Funded Warrant issued in November 2025 offering (incorporated by reference from exhibit 4.1 of the Form 8-K filed November 19, 2025)

4.10	Form of Series C Warrant issued in November 2025 offering (incorporated by reference from exhibit 4.2 of the Form 8-K filed November 19, 2025)

10.1**	Employment Letter dated January 4, 2022 between the Company and Robert Schwartz (incorporated by reference from exhibit 6.1 of the Form 1-A POS, file number 024-12296, filed January 19, 2024)

10.2**	Amended and Restated Consulting Agreement effective January 4, 2022 between the Company and Landy Toth (incorporated by reference from exhibit 6.2 of the Form 1-A POS, file number 024-12296, filed January 19, 2024)

10.3**	Employment Agreement between the Company and Lori Bisson dated June 30, 2023 (incorporated by reference from exhibit 6.3 of the Form 1-A POS, file number 024-12296, filed January 19, 2024)

10.4**	Employment Agreement between the Company and Trent Smith dated July 24, 2023 (incorporated by reference from exhibit 6.4 of the Form 1-A POS, file number 024-12296, filed January 19, 2024)

10.5**	Autonomix Medical, Inc. 2023 Stock Plan, as amended and restated and forms of award agreements (incorporated by reference from exhibit 4.4 of the Form S-8 (file number 333-294858)

10.6	Form of Indemnification Agreement with Executive Officers and Directors of the Company (incorporated by reference from exhibit 6.6 of the Form 1-A POS, file number 024-12296, filed January 19, 2024)

10.7	Form of Lock-Up Agreement to be entered into between the Company and its officers and directors (incorporated by reference from exhibit 6.7 of the Form 1-A POS, file number 024-12296, filed January 19, 2024)

10.8+	Exclusive License Agreement dated December 21, 2021 between Autonomix Medical, Inc. and Impulse Medical, Inc. (incorporated by reference from exhibit 6.8 of the Form 1-A POS, file number 024-12296, filed January 19, 2024)

10.9	Exclusive License Termination Agreement dated July 7, 2023 between Autonomix Medical, Inc. and Impulse Medical, Inc. (incorporated by reference from exhibit 6.9 of the Form 1-A POS, file number 024-12296, filed January 19, 2024)

10.10**	Employment Agreement between Brad Hauser and Autonomix Medical, Inc. dated June 17, 2024. (incorporated by reference from exhibit 10.1 of the Form 8-K filed June 17, 2024)

10.11**	Employment Agreement between Lori Bisson and Autonomix Medical, Inc. dated June 17, 2024. (incorporated by reference from exhibit 10.2 of the Form 8-K filed June 17, 2024)

10.12	License Agreement between Autonomix Medical, Inc. and RF Innovations, Inc. (incorporated by reference from exhibit 10.1 of the Form 8-K filed July 15, 2024)

10.13**	Non-Employee Director Compensation Plan (incorporated by reference from exhibit 10.2 of the Form 10-Q filed November 8, 2024)

10.14	At Market Issuance Sales Agreement, dated February 28, 2025, by and between Autonomix Medical, Inc. and Ladenburg Thalmann & Co. Inc. (incorporated by reference from exhibit 1.1 of the Form 8-K filed February 28, 2025)

10.15**	Stock Option Cancellation and Severance Agreement between Autonomix Medical, Inc. and Brad Hauser dated August 11, 2025 (incorporated by reference from exhibit 10.2 of the Form 10-Q filed August 13, 2025)

10.16**	Stock Option Cancellation and Severance Agreement between Autonomix Medical, Inc. and Trent Smith dated August 11, 2025 (incorporated by reference from exhibit 10.3 of the Form 10-Q filed August 13, 2025)

10.17**	Stock Option Cancellation and Severance Agreement between Autonomix Medical, Inc. and Landy Toth dated August 11, 2025 (incorporated by reference from exhibit 10.4 of the Form 10-Q filed August 13, 2025)

10.18 **	Stock Option Cancellation and Severance Agreement between Autonomix Medical, Inc. and Robert Schwartz dated August 11, 2025 (incorporated by reference from exhibit 10.5 of the Form 10-Q filed August 13, 2025)